Abstract: The present disclosure provides multicistronic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.

Abstract: The present disclosure provides methods for ameliorating or treating a neurological condition or disease in a subject in need of treatment thereof by administering to the subject a therapeutically effective amount of a composition comprising (i) a recombinant DNA (rDNA), wherein the rDNA comprises a human nuclear hormone receptor (hNHR) gene or a fragment thereof; and (ii) a delivery vehicle adapted for delivering said rDNA to neurological cells or tissues to ameliorate or treat said neurological condition or disease.